Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 48,537 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: AS+ Clear all

Conditions: Suicidal Ideation, Circadian Rhythm Disorders, Sleep Deprivation, Sleep Wake Disorders
Interventions: Sleep Pressure Manipulation; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 55 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Artifical Inteligence, Cardiology, Breast Cancer, Sepsis
Interventions: AI-PERSONALIZED CLINICAL DECISION SUPPORT; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 300,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders
Interventions: Injectable extended-release buprenorphine, Sublingual buprenorphine-naloxone; Drug
Lead sponsor: Yih-Ing Hser; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: El Dorado, Arkansas • Garberville, California • Gibson City, Illinois + 4 more

Conditions: Parenchymous Tissue Surgical Bleeding
Interventions: Fibrin Sealant Grifols, Surgicel®; Biological · Device
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: Not listed
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 26
States / cities: Loma Linda, California • Los Angeles, California • New Haven, Connecticut + 21 more

Conditions: Thyroid Cancer, Graves Disease
Interventions: Cervical Collar Therapy Indicator (COTI); Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Neurosciences
Interventions: Behavioral testing during neuronal recordings; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Hydration
Interventions: Hydration Active Product 1, Hydration Active Product 2, Hydration Active Product 3; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 660 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Prostate Cancer
Interventions: MDX-010 / MDX-010 + Docetaxel; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 11
States / cities: Tucson, Arizona • Long Beach, California • San Diego, California + 7 more

Conditions: Healthy
Interventions: LY3484356, Omeprazole, Itraconazole, Carbamazepine, Midazolam; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Stroke, Secondary Stroke Prevention
Interventions: Care Management+Community Health Worker, Usual Care; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 6
States / cities: Downey, California • Los Angeles, California • Sylmar, California + 1 more

Conditions: Multiple Myeloma
Interventions: Oprozomib, Dexamethasone; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 10
States / cities: Los Angeles, California • Tampa, Florida • Westwood, Kansas + 6 more

Conditions: Phantom Limb Pain (PLP)
Interventions: virtual reality therapy, matched control group; Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Pancreatic Cancer
Interventions: capecitabine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: rV-DF3/MUC1; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 4
States / cities: Boston, Massachusetts

Conditions: Relationship Distress
Interventions: Brief Relationship Checkup (BRC); Behavioral
Lead sponsor: Canandaigua VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Canandaigua, New York

Conditions: High Utilizers of Hospital Care
Interventions: Link2Care; Other
Lead sponsor: Abdul Latif Jameel Poverty Action Lab; Other
Eligibility: 19 Years to 80 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Camden, New Jersey

Conditions: Neoplasms
Interventions: letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 6
States / cities: Tampa, Florida • Ann Arbor, Michigan • St Louis, Missouri + 3 more

Conditions: Advanced Solid Tumors, Malignant Neoplasm
Interventions: MK-3120; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 7
States / cities: Birmingham, Alabama • Miami, Florida • Hackensack, New Jersey + 4 more

Conditions: Obesity, Childhood, Physical Activity, Food Intake, Rural Health
Interventions: NU-HOME Intervention; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 7 Years to 99 Years
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension, Diabete Type 2
Interventions: Treatment as Usual Plus Occupational Therapy, Treatment as Usual; Behavioral
Lead sponsor: University of Indianapolis; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: Busulfan, Cyclophosphamide; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 6 Months to 65 Years
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Kidney Failures, Acute
Interventions: Intra-Renal Fenoldopam, Furosemide; Drug
Lead sponsor: Southeast Renal Research Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chattanooga, Tennessee

Conditions: HIV-DDI
Interventions: Riociguat (Adempas, BAY 63-2521), ATRIPLA, COMPLERA, STRIBILD, TRIUMEQ, Antiretroviral protease inhibitor; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Orlando, Florida • Boston, Massachusetts

Conditions: Suicide, Risk Reduction
Interventions: Building Stronger Allies, Health Education Training; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Fort Campbell North, Kentucky

Search by objective public record fields.

Mind After Midnight

Safe and Explainable AI

Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)

Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries

Personalized Treatment in Thyroid Disorders

Studying the Neuronal Basis of Human Social Cognition

An Open Label Trial Assessing the Impact of a Hydration Formula on Overall Health

Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

A Study of LY3484356 in Healthy Female Participants

The SUCCEED Trial of Secondary Stroke Prevention

Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

Immersive Healing: The Therapeutic Potential of Virtual Reality

Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

Vaccine Therapy in Treating Patients With Metastatic Breast Cancer

A Pilot of the Brief Relationship Checkup

Health Care Hotspotting: A Randomized Controlled Trial

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME

Effect of Occupational Therapy in Promoting Medication Adherence

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury

Interaction With HIV Antiretroviral Agents

Building Stronger Allies